Regeneron Pharmaceuticals, Inc. (REGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
514.05+5.74 (+1.13%)
At close: 1:00PM EST
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 508.31 |
| Open | 513.42 |
| Bid | 510.01 x 800 |
| Ask | 514.05 x 800 |
| Day's Range | 509.20 - 518.92 |
| 52 Week Range | 328.13 - 664.64 |
| Volume | 498,175 |
| Avg. Volume | 969,509 |
| Market Cap | 54.852B |
| Beta (5Y Monthly) | 0.40 |
| PE Ratio (TTM) | 18.84 |
| EPS (TTM) | 27.29 |
| Earnings Date | Feb 04, 2021 - Feb 08, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 673.17 |
- Zacks
Is Regeneron Pharmaceuticals (REGN) a Worthy Stock Now?
Let's see if Regeneron Pharmaceuticals (REGN) stock is a good choice for value-oriented investors right now from multiple angles.
- Zacks
Biotech Stock Roundup: REGN's Cocktail Gets EUA, GILD & AMGN Provide Updates & More
Pipeline and regulatory updates take centerstage in the biotech sector as Regeneron (REGN) and Gilead Sciences (GILD), among others, provide updates on their pipeline candidates.
- Zacks
Alnylam (ALNY) Gets FDA Nod for Oxlumo to Treat Renal Disease
The FDA approves Alnylam's (ALNY) Oxlumo injection for subcutaneous use, to lower urinary oxalate levels in pediatric and adult patients with primary hyperoxaluria type 1.
© 2020 Verizon Media. All rights reserved.
